Vivoryon Therapeutics N.V. Stock
Stocks
VVY
NL00150002Q7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Amsterdam
11:55:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 1.100 EUR | +0.92% |
|
-0.90% | -22.54% |
| 08-06 | Vivoryon Therapeutics N.V., H1 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 32.58M 36.66M 30.4M 27.71M 52.27M 3.52B 52.75M 368M 143M 1.8B 138M 135M 5.78B | P/E 2026 * |
-2.89x | P/E 2027 * | -2.97x |
|---|---|---|---|---|---|
| Enterprise Value | 36.9M 41.53M 34.44M 31.39M 59.2M 3.99B 59.75M 417M 161M 2.04B 156M 153M 6.55B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
95.15% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext AmsterdamEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| VVY | Real-time | |
Tradegate
| 05Y | Real-time | |
|
CBOE
| VVY | Real-time | |
|
Deutsche Boerse AG
| 05Y | Delayed | |
|
CBOE
| 0R3M | Real-time | |
|
Boerse Muenchen
| 05Y | Real-time | |
|
Börse Stuttgart
| 05Y | Delayed | |
|
Wiener Boerse
| VVYN | End-of-day quote |
Last Transcript: Vivoryon Therapeutics N.V.
| 1 day | +0.92% | ||
| 1 week | -0.90% | ||
| 1 month | -2.65% | ||
| 6 months | -17.29% | ||
| Current year | -22.54% |
| 1 week | 1.06 |  | 1.11 |
| 1 month | 1.06 | | 1.14 |
| Current year | 1 | | 1.65 |
| 1 year | 1 | | 1.84 |
| 3 years | 0.41 | | 11.68 |
| 5 years | 0.41 | | 20.77 |
| 10 years | 0.41 | | 23.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 66 | 2023-08-13 |
Marcus Irsfeld
DFI | Director of Finance/CFO | - | 2025-11-30 |
Julia Neugebauer
COO | Chief Operating Officer | - | 2025-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 2006-12-31 | |
Frank Weber
BRD | Director/Board Member | 66 | 2023-09-14 |
| Director/Board Member | 58 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/23/25 | Free | Chief Operating Officer | 20,000 | 0.0767% | ||
| 10/23/25 | Buy | Chief Executive Officer | 135,000 | 0.5179% | ||
| 10/23/25 | Free | 20,000 | 0.0767% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.92% | -0.90% | -32.52% | -89.68% | 36.66M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | |
| Average | -0.11% | -0.62% | +44.12% | +106.72% | 39.06B | |
| Weighted average by Cap. | +0.12% | -0.84% | +56.95% | +138.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -10.4M -11.71M -9.71M -8.85M -16.69M -1.13B -16.84M -117M -45.52M -575M -43.95M -42.99M -1.85B | -10.4M -11.71M -9.71M -8.85M -16.69M -1.13B -16.84M -117M -45.52M -575M -43.95M -42.99M -1.85B |
| Net Debt | 4.32M 4.86M 4.03M 3.68M 6.93M 467M 7M 48.79M 18.91M 239M 18.25M 17.86M 767M | 13.03M 14.67M 12.16M 11.08M 20.91M 1.41B 21.1M 147M 57.03M 721M 55.06M 53.87M 2.31B |
Employees
13
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | €1.100 | +0.92% | 12,712 |
| 26-10-01 | €1.090 | -0.91% | 1,419 |
| 26-09-30 | €1.100 | -0.90% | 30,947 |
| 26-09-29 | €1.110 | +0.91% | 26,163 |
| 26-09-28 | €1.100 | -0.90% | 9,930 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.100EUR
Average target price
6.850EUR
Spread / Average Target
+522.73%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VVY Stock
Select your edition
All financial news and data tailored to specific country editions
